Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 33Myelodysplastic Syndromes 9Recurrence 7Lymphoma, Large B-Cell, Diffuse 5Hodgkin Disease 5Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Leukemia 2Wilms Tumor 1TP53 1Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden 1Primary Malignant Neoplasm of Ovary 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Peripheral Blood Stem Cell Transplantation 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Malignant Solid Tumor 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid 1Hematopoietic System--Cancer 1Graft vs Host Disease 1Extranodal Extension 1Esophageal Squamous Cell Carcinoma 1

Interventions

Decitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Extranodal Extension × Decitabine × Clear all
NCT05816746 2023-05-09

Decitabine and Anti-PD-1 in R/R DLBCL

Chinese PLA General Hospital

Phase 2 Unknown
20 enrolled
Lymphoid

Extranodal Extension, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡